Efzofitimod Fails to Lower Steroid Needs in Sarcoidosis
Adults with pulmonary sarcoidosis may see no change in steroid dependency after a recent Phase 3 study of the drug.
Updated on Oct. 29, 2026 in Asthma
Live Poll
Should medical studies that miss primary endpoints still be considered significant advancements for patient care?
The Phase 3 EFZO-FIT trial results published in The Lancet Respiratory Medicine show that the drug efzofitimod did not reach its primary endpoint of reducing oral corticosteroid doses in patients with pulmonary sarcoidosis. While the trial failed this main objective, the drug was well-tolerated and showed improvements in patient-reported outcomes over 48 weeks.
Why it matters
Pulmonary sarcoidosis often requires long-term corticosteroid use, which can lead to significant side effects for the estimated 160,000 Americans living with the condition. This trial provides critical evidence that while efzofitimod may improve patient-reported symptoms, it did not demonstrate the expected efficacy in tapering steroid reliance compared to a placebo.
In a 48-week Phase 3 trial of 268 patients, efzofitimod treatment did not result in a statistically significant reduction in mean daily oral corticosteroid doses compared to a placebo. While the trial met safety expectations, the reduction in steroid dependency was not statistically supported.
The players
aTyr Pharma
A San Diego-based biotherapeutics company focused on developing therapies for inflammatory diseases including pulmonary sarcoidosis.
The details
The EFZO-FIT trial utilized a protocol-guided steroid taper over the initial 12 weeks, followed by further tapering or rescue medication as needed through week 48. Researchers evaluated efzofitimod at 3.0 mg/kg and 5.0 mg/kg to determine if the therapy could successfully minimize the need for high-dose steroids. Although the drug failed to meet its primary steroid-reduction goal, it maintained a safety profile consistent with earlier studies and improved several patient-reported health metrics.
Timeline
• The study monitored efficacy and safety for a duration of 48 weeks.
• The EFZO-FIT trial results were officially published on Oct 29, 2026.
Health Landscape
Developing effective alternatives to long-term corticosteroid treatment remains a major challenge in the management of pulmonary sarcoidosis. These findings update the broader research landscape by clarifying the limitations of efzofitimod in reducing steroid use compared to current standard care.
If you are managing pulmonary sarcoidosis, discuss these trial findings with your physician to understand how they may relate to your current corticosteroid treatment plan. Because individual health needs vary significantly, any adjustments to your medication regimen should only be made in consultation with your specialist.
The takeaway
While this study suggests efzofitimod did not meet its goal of lowering steroid use, it underscores the difficulty of treating chronic pulmonary sarcoidosis without long-term medication. Patients should continue working closely with their pulmonologist to track disease symptoms and monitor steroid side effects.
Further reading
For more information on the latest clinical advancements in respiratory care, visit our Asthma section.
More information
Review the full study findings in The Lancet clinical trial study abstract00283-3/abstract).
Source note: This article includes information reported by The Manila times.
Live Poll
Should medical studies that miss primary endpoints still be considered significant advancements for patient care?
